Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses emerging biomarkers in non–small cell lung cancer (NSCLC).
Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses emerging biomarkers in non—small cell lung cancer (NSCLC).
PD-L1, and more recently, tumor mutation burden are what physicians call “surrogate” biomarkers, says Bauml. They may indicate a response, but they are not a direct understanding of what is happening in the body or what is causing these therapies to work.
Gene expression profiling and T-cell exhaustion profiling are 2 emerging biomarkers that can change the way physicians use novel therapies. Gene expression profiling is looking at RNA expression of various genes. There has been accordance of this in PD-L1, says Bauml. It has the potential to be more indicative of response to immunotherapy than PD-L1 alone.
However, in the IMpower150 trial, researchers found that it was not much better than PD-L1 alone. T-cell exhaustion profiling is just beginning to gain exposure in the field. This evaluates certain features of the T cells.